Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c, FY Guidance Beats
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.32 +0.48%
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $59.77 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $168.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Carnival shares drop despite earnings beat on weak guidance
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
